Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis

被引：0

作者：

Montalban, X. ^{[1
]}

Hemmer, B. ^{[2
]}

Rammohan, K. ^{[3
]}

Giovannoni, G. ^{[4
]}

de Seze, J. ^{[5
]}

Bar-Or, A. ^{[6
]}

Arnold, D. ^{[6
]}

Sauter, A. ^{[7
]}

Leppert, D. ^{[8
]}

Chin, P. ^{[9
]}

Garren, H. ^{[8
]}

Messier, M. ^{[8
]}

Wolinski, J. ^{[10
]}

Kakarieka, A. ^{[8
]}

Masterman, D. ^{[9
]}

机构：

[1] Vall dHebron Univ Hosp, Dept Neurol Neuroimmunol, Barcelona, Spain

[2] Tech Univ Munich, Neurol, D-80290 Munich, Germany

[3] Univ Miami Hlth Syst, MS Ctr Excellence, Miami, FL USA

[4] Barts & London Queen Marys Sch Med & Dent, Neurosci, London, England

[5] Univ Hosp Strasbourg, Neurol, Strasbourg, France

[6] McGill Univ, Montreal Neurol Inst & Hosp, Montreal, PQ, Canada

[7] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland

[8] F Hoffmann La Roche & Co Ltd, Neurosci, CH-4002 Basel, Switzerland

[9] Genentech Roche, Neurosci, San Francisco, CA USA

[10] Univ Texas Houston, Sch Med, Neurosci, Houston, TX USA

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2015年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

F3049

引用

页码：706 / 706

页数：1

共 50 条

[1] Phase III Study of Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis: ORATORIO Study Design
Montalban, Xavier
Wolinsky, Jerry
Yin, Ming
Leppert, David
Glanzman, Robert
Chin, Peter
NEUROLOGY, 2011, 76 (09) : A319 - A320
[2] Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis
Hauser, S.
Comi, G.
Hartung, H. -P.
Selmaj, K.
Traboulsee, A.
Bar-Or, A.
Arnold, D.
Klingelschmitt, G.
Leppert, D.
Kakarieka, A.
Lublin, F.
Garren, H.
Kappos, L.
EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 752 - 752
[3] Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive Multiple Sclerosis from the Phase III ORATORIO Study
Kappos, L.
Montalban, X.
Hauser, S. L.
Julian, L.
Manfrini, M.
Belachew, S.
Model, F.
Hubeaux, S.
Bar-or, A.
Wolinsky, J. S.
EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 431 - 431
[4] Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial
Fox, Edward J.
Markowitz, Clyde
Applebee, Angela
Montalban, Xavier
Wolinsky, Jerry S.
Belachew, Sihbeshih
Fiore, Damian
Pei, Jinglan
Musch, Bruno
Giovannoni, Gavin
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (14) : 1862 - 1870
[5] Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study
Fox, E. J.
Markowitz, C.
Applebee, A.
Montalban, X.
Wolinsky, J. S.
Belachew, S.
Fiore, D.
Han, J.
Musch, B.
Giovannoni, G.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 658 - 659
[6] Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial
Wolisnky, J. S.
Brochet, B.
Montalban, X.
Naismith, R. T.
Manfrini, M.
Garas, M.
Villoslada, P.
Model, F.
Hubeaux, S.
Kappos, L.
Hauser, S. L.
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 490 - 491
[7] Effect of Ocrelizumab on Severe Progression of Upper Extremity Impairment in Patients with Primary Progressive Multiple Sclerosis in ORATORIO
Fox, Edward J.
Markowitz, Clyde
Applebee, Angela
Montalban, Xavier
Wolinsky, Jerry S.
Belachew, Shibeshih
Fiore, Damian
Pei, Jinglan
Musch, Bruno
Giovannoni, Gavin
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 33 - 34
[8] Demographics and baseline disease characteristics of patients with relapsing multiple sclerosis from Kenya participating in the CHIMES trial
Sokhi, D. S.
Hooker, J.
Williams, M. J.
Amezcua, L.
Shamshudin, A.
Hussein, Y. E.
Betti, P.
Amariati, H.
Karimi, N.
Gondi, S.
Pei, J.
Bulhan, H.
Okaka, D.
Acosta, J.
Saleh, M.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 841 - 841
[9] Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO Trials
Bar-Or, Amit
Thanei, Gian-Andrea
Harp, Christopher
Cross, Anne
Fiore, Damian
Hauser, Stephen
Jia, Xiaoming
Kappos, Ludwig
Koendgen, Harold
Kuhle, Jens
Leppert, David
Manfrini, Marianna
Model, Fabian
Sauter, Annette
Herman, Ann
NEUROLOGY, 2020, 94 (15)
[10] EVALUATION OF NO EVIDENCE OF PROGRESSION OR ACTIVE DISEASE (NEPAD) IN PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN THE ORATORIO TRIAL
Wolinsky, Jerry
Montalban, Xavier
Kappos, Ludwig
Hauser, Stephen
Giovannoni, Gavin
de Seze, Jerome
Bar-Or, Amit
Masterman, Donna
Bernasconi, Corrado
Wei, Wei
Garren, Hideki
Chin, Peter
Belachew, Shibeshih
Arnold, Doug L.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 (05):

← 1 2 3 4 5 →